ArticleAIDS (London, England)2025
Severe acute respiratory syndrome coronavirus-2 antibody prevalence in adults with HIV.
Article in AIDS (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo measure severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) antibody seroprevalence within a cohort of adults with HIV and correlate demographics with response rates to SARS CoV-2 vaccination.
designInitial vaccine trials for SARS CoV-2 did not examine efficacy in people with HIV. We undertook the SCAPE-HIV study from April 2021 to November 2022 to focus on vaccine response in this population to guide future vaccine scheduling.
methodsParticipants completed a retrospective questionnaire. Nucleocapsid and spike antibodies to SARS CoV-2 (anti-N and anti-S) were tested. Demographic and HIV factors (CD4 + cell count, viral load) were correlated with quantitative serological outcomes. Anti-S titres less than 400 U/ml were considered low level. Follow-up was performed in a subset post third vaccination.
resultsSix hundred and twelve participants completed the study questionnaire, 520 were included in the final analysis. Most participants received either ChAdOx1-S recombinant vaccine or the BNT162b2 mRNA vaccine for the first two doses. Almost all participants (99.2%) in the main group had an anti-S antibody detected above the assay cutoff (>0.8 U/ml). Most participants (77.3%) had anti-S titres greater than 400 U/ml, with the median titre 1734 U/ml. Age over 60 years was significantly associated with lower (<400 U/ml) anti-S antibody titre ( P < 0.0001).
conclusionWe demonstrate a high rate of anti-S seropositivity following SARS-CoV-2 vaccination in people with HIV. Age over 60 was the only parameter found to be associated with a lower anti-S antibody titre. Our findings suggest that COVID-19 vaccine scheduling should target older persons with HIV in line with the general population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.